

Press Release

Proposed Withdrawal of DEPB Scheme Not to Impact Strides

Bangalore, May 24, 2011: With reference to the proposal by the Government of India to withdraw the Duty Entitlement Passbook Scheme (DEPB) and the resultant media coverage on its likely impact on the pharmaceutical industry, **Strides Arcolab wishes to clarify that such a withdrawal will not have any impact on the Company.** There are currently no DEPB claims being made by the Company as the Company's exports are from 100% EOUs.

This clarification is being issued as the Company has been receiving queries from the investor community on the impact, if any, on the Company in the event that the DEPB scheme is withdrawn.

About Strides Arcolab

Strides Arcolab, listed on the Bombay Stock Exchange Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical company headquartered in Bangalore, India, that develops and manufactures a wide range of IP-led niche pharmaceutical products with an emphasis on sterile injectables.

The company has 14 manufacturing facilities across 6 countries with presence in more than 75 countries in developed and emerging markets. Manufacturing is ably supported by a 350-scientist strong global R&D Centre located in Bangalore.

Additional information is available at the Company's website at www.stridesarco.com.

For further information, please contact:

<u>Strides</u>	<u>PR Consultancy</u>
<u>Investors:</u>	Corporate Voice/Weber Shandwick
Kannan. N - +98450 54745	Mahesh Nair,
Ajay Singh - +91 80 66580813	+91 9880376648
	maheshn@corvoshandwick.co.in
<u>Media:</u>	
Melissa Arulappan - +91 98450 22389	Hiba Kunil
	+91 98807 26372
	hiba@corvoshandwick.co.in

